CA
CASBF.US CanSino Biologics Inc
- Market cap
- USD 766M
- P/E
- 103.3x
- P/B
- 1.13x
- ROE
- 0.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CASBF.US undervalued?
Graham numberCASBF.US trades 127.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CanSino Biologics Inc fundamental analysis
No fundamental analysis for CanSino Biologics Inc yet.
CanSino Biologics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary va…
Full company profileCanSino Biologics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CanSino Biologics Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.20M | -602K | 1.13M | 2.28M | 24.9M | 4.30B | 1.03B | 345M | 825M | 1.03B | 1.17B |
| Gross Profit | -43.5M | -68.7M | -113M | 2.14M | 4.74M | 3.00B | -187M | -876M | 580M | 682M | 879M |
| Operating Income | -52.7M | -63.8M | -139M | -200M | -398M | 1.94B | -1.37B | -2.04B | -403M | -113M | -32.6M |
| EBITDA | -45.1M | -67.1M | -126M | -195M | -486M | 1.87B | -1.30B | -1.65B | -110M | 61.0M | 32.3M |
| Net Income | -49.9M | -64.5M | -138M | -157M | -397M | 1.91B | -909M | -1.48B | -379M | 27.2M | 22.0M |
| EPS | -0.23 | -0.30 | -0.88 | -0.63 | -1.60 | 7.74 | -3.69 | -6.01 | -1.53 | 0.11 | 0.09 |
| Balance Sheet | |||||||||||
| Total Assets | 326M | 866M | 796M | 1.78B | 6.75B | 11.9B | 11.5B | 9.32B | 7.96B | 7.19B | 6.84B |
| Total Liabilities | 112M | 259M | 294M | 314M | 677M | 3.33B | 4.22B | 4.03B | 3.05B | 2.05B | 1.84B |
| Shareholders' Equity | 214M | 607M | 502M | 1.47B | 6.07B | 8.00B | 6.75B | 5.27B | 4.91B | 4.96B | 5.01B |
| Cash & Short-term Investments | 147M | 421M | 197M | 755M | 5.11B | 7.78B | 5.95B | 4.12B | 3.20B | 2.65B | 1.77B |
| Total Debt | 69.3M | 108M | 150M | 167M | 143M | 1.37B | 2.70B | 2.70B | 2.01B | 1.29B | 929M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.4M | -56.3M | -124M | -170M | -469M | 2.01B | -1.89B | -908M | -169M | 32.5M | 30.5M |
| Capital Expenditure | 126M | 186M | 161M | 117M | 271M | 1.20B | 1.08B | 610M | 458M | 185M | 126M |
| Free Cash Flow | -160M | -242M | -284M | -287M | -740M | 811M | -2.96B | -1.53B | -626M | -153M | -95.5M |
| Ratios | |||||||||||
| ROE | -23.2% | -10.6% | -27.5% | -10.7% | -6.5% | 23.9% | -13.5% | -28.1% | -7.7% | 0.5% | 0.4% |
| ROA | -15.3% | -7.4% | -17.4% | -8.8% | -5.9% | 16.1% | -7.9% | -15.9% | -4.8% | 0.4% | 0.3% |
| Net Profit Margin | -608.3% | - | -12,215.6% | -6,865.5% | -1,593.6% | 44.5% | -88.2% | -429.6% | -45.9% | 2.6% | 1.9% |
| Debt to Equity | 0.32x | 0.18x | 0.30x | 0.11x | 0.02x | 0.17x | 0.40x | 0.51x | 0.41x | 0.26x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CanSino Biologics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 13, 2022
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | CNY 63.8M | 0.26 | - |
| 2023 | USD 3.63M | 0.01 | - |
| 2022 | CNY 194M | 0.79 | - |
| 2021 | USD 14.1M | 0.06 | 0.7% |
| 2020 | USD 6.69M | 0.03 | - |
| 2019 | USD 8.78M | 0.04 | - |
| 2018 | USD 7.59M | 0.05 | - |
| 2017 | USD 4.63M | 0.02 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CanSino Biologics Inc
- Insiders 26.32%
- Institutions 14.18%
- Public & others 59.50%
- Shares outstanding 133M
- Free float 151M
CanSino Biologics Inc company profile
- Company name
- CanSino Biologics Inc
- Ticker
- CASBF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,134
- Fiscal year end
- December
- Address
- 401-420, Biomedical Park, Tianjin, China, 300457
- Phone
- 86 022 5821 3600
- Website
- cansinotech.com
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
CanSino Biologics Inc management
10- Dr. Xuefeng Yu Ph.D.Co-Founder, Executive Chairman, CEO & GM · born 1964
- Dr. Shou-Bai Chao Ph.D.COO, Deputy GM & Executive Director · born 1963
- Ms. Jing WangChief Commercial Officer, Deputy GM & Executive Director · born 1981
- Dr. Tao Zhu Ph.D.Co-Founder, Deputy GM & Chief Scientific Officer · born 1973
- Dr. Dongxu Qiu MBA, Ph.D.Co-Founder, Executive VP & Deputy GM · born 1960
- Ming LiuActing Head of Finance
- Bei Bei GaoAccounting Supervisor
- Mr. Chunlin XinSenior Director of New Technology Department
- Mr. Yonghui WuVice President of Marketing
- Mr. Jin CuiBoard Secretary · born 1987